---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-24-004298"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:26:23.966664+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tonix Q4 2023 net loss $27.3M; cash down to $24.9M; Tonmya NDA on track for H2 2024

## Summary
- Q4 2023 net loss $27.3M ($0.86/share) vs $34.1M ($3.42) in Q4 2022; full year net product revenue $7.8M.
- Cash and equivalents $24.9M at Dec 31, 2023 vs $120.2M at Dec 31, 2022; net cash used in operations $102M.
- Pre-NDA meeting with FDA for Tonmya (cyclobenzaprine SL) for fibromyalgia scheduled Q2 2024; NDA submission planned H2 2024.
- Raised $4.4M in registered direct offering on March 28, 2024; also $11M term loan executed Dec 2023.
- Completed transition to fully integrated pharma with marketed migraine products Zembrace and Tosymra.

## SEC filing metadata
- accession: 0001999371-24-004298
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937124004298/0001999371-24-004298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937124004298/tnxp_8k-040124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-24-004298
- JSON: https://secwatch.observer/filing/0001999371-24-004298.json
- Plain text: https://secwatch.observer/filing/0001999371-24-004298.txt

## Key facts
- Earnings Releases
  Tonix Pharmaceuticals Holding Corp. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On April 1, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000199937124004298/0001999371-24-004298-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.